Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEXAPRO vs LUVOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
Obsessive-compulsive disorder (OCD),Social anxiety disorder,Panic disorder,Premenstrual dysphoric disorder (PMDD),Bulimia nervosa,Post-traumatic stress disorder (PTSD)
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Primarily hepatic via CYP1A2; minor pathways via CYP2D6; active metabolites minimal.
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
Approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
The apparent volume of distribution is about 4.7 L/kg, indicating extensive extravascular distribution and tissue binding, which contributes to its long half-life.
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
Oral bioavailability is approximately 53% after a single dose, with no significant food effect. Bioavailability may be higher under steady-state conditions due to saturation of first-pass metabolism.
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥20 m L/min). Avoid use in severe renal impairment (Cr Cl <20 m L/min) due to lack of data.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Child-Pugh Class A: no dose adjustment; Child-Pugh Class B: reduce dose by 50% (start 25 mg/day, titrate cautiously); Child-Pugh Class C: contraindicated.
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
Children (8-17 years): start 25 mg orally once daily at bedtime; increase by 25 mg increments every 4-7 days to target dose; for OCD: 25-200 mg/day; maximum 200 mg/day. Weight not routinely used; dosing based on age and response.
Initial 5 mg orally once daily; maximum 10 mg once daily.
Start 25 mg orally once daily at bedtime; titrate slowly (increases of 25 mg every 1-2 weeks); usual maximum 200 mg/day due to increased sensitivity and risk of hyponatremia.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Suicidality risk in young patients,Serotonin syndrome,Activation of mania/hypomania,Seizure risk,Abnormal bleeding,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction,Discontinuation syndrome
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
Concomitant use with MAOIs,Concomitant use with triptans,Hypersensitivity to fluvoxamine or any excipient,Pregnancy (relative)
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
Avoid grapefruit juice as it inhibits CYP1A2 and can increase fluvoxamine serum concentrations, leading to toxicity. No other significant food interactions; however, taking with food may reduce GI upset.
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hypertension of the newborn (PPHN) (OR 2.1). Second/third trimester: Late pregnancy exposure may increase risk of preterm birth, low birth weight, and neonatal adaptation syndrome (e.g., respiratory distress, feeding difficulties, irritability).
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Fluvoxamine is excreted into breast milk; M/P ratio ranges from 0.29 to 0.59. Relative infant dose is approximately 1.7% of maternal weight-adjusted dose. Low risk of adverse effects in breastfed infants; monitor for drowsiness, poor feeding, and weight gain. AAP classifies as compatible with breastfeeding.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
Plasma levels of fluvoxamine may decrease during pregnancy due to increased volume of distribution and enhanced hepatic metabolism. Dose adjustment may be necessary; consider therapeutic drug monitoring to maintain efficacy. Usually, dose can be increased by 50-100% in third trimester, with gradual reduction postpartum to pre-pregnancy levels.
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
Luvox (fluvoxamine) is a selective serotonin reuptake inhibitor (SSRI) approved for obsessive-compulsive disorder (OCD) and social anxiety disorder. It has a short half-life (15-22 hours) and no active metabolites, making it suitable for patients with hepatic impairment. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic agents. Luvox is a potent inhibitor of CYP1A2, affecting metabolism of drugs like clozapine, olanzapine, theophylline, and tizanidine. Titrate slowly; start at 50 mg nightly and increase by 50 mg every 4-7 days to a max of 300 mg daily (divided for doses >100 mg). Discontinuation syndrome is common; taper gradually.
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
Take Luvox exactly as prescribed, usually once daily at bedtime to minimize daytime drowsiness.,It may take several weeks to feel the full effect; do not stop abruptly without consulting your doctor.,Avoid grapefruit juice, which can increase Luvox levels and side effects.,Report any signs of serotonin syndrome (hallucinations, agitation, rapid heart rate, fever, muscle stiffness) immediately.,Do not drive or operate heavy machinery until you know how Luvox affects you, as it can cause drowsiness or dizziness.,Limit alcohol consumption; alcohol can worsen sedation and increase risk of side effects.,Store at room temperature, away from moisture and heat.
No interactions on record
"Tetracycline may inhibit the metabolism of Fluvoxamine via cytochrome P450 enzyme interference, leading to increased Fluvoxamine plasma concentrations. This elevation potentiates serotonergic effects and may precipitate serotonin syndrome, characterized by hyperthermia, autonomic instability, and neuromuscular abnormalities. Concurrent use requires careful monitoring for signs of toxicity such as agitation, confusion, and tachycardia."
"Dexlansoprazole, a proton pump inhibitor (PPI), may inhibit CYP1A2, the primary enzyme responsible for metabolizing fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). This interaction can lead to increased plasma concentrations of fluvoxamine, potentiating its serotonergic effects and risk of dose-dependent adverse events such as nausea, somnolence, and serotonin syndrome. Clinicians should monitor for signs of fluvoxamine toxicity and consider dose adjustment when initiating or discontinuing dexlansoprazole."
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEXAPRO vs LUVOX, answered by our medical review team.
LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. LUVOX is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEXAPRO and LUVOX depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. The standard adult dose of LUVOX is: Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEXAPRO and LUVOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. LUVOX is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hype. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.